Michael Rosenblatt - Merck Executive Vice President Chief Medical Officer

MRCK34 Stock  BRL 82.64  0.61  0.74%   

President

Dr. Michael Rosenblatt, M.D., is Executive Vice President, Chief Medical Officer of Merck Co., Inc. He is responsible for the Companys primary voice to the global medical community on critical issues such as patient safety and oversight for the Companys Global Center for Scientific Affairs. Prior to December 2009, Dr. Rosenblatt was the Dean of Tufts University School of Medicine since 2003. since 2009.
Age 67
Tenure 15 years
Professional MarksPh.D
Phone908 740 4000
Webhttps://www.merck.com

Merck Management Efficiency

The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 30.69 B in total debt with debt to equity ratio (D/E) of 97.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Merck has a current ratio of 1.34, which is within standard range for the sector. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Matthew FriedrichCognizant Technology Solutions
51
Sumithra GomatamCognizant Technology Solutions
50
Allen ShaheenCognizant Technology Solutions
55
Gregory TombZoom Video Communications
57
David NelsonCognizant Technology Solutions
N/A
Santosh ThomasCognizant Technology Solutions
49
Debashis ChatterjeeCognizant Technology Solutions
52
Robert TelesmanicCognizant Technology Solutions
56
Rajeev MehtaCognizant Technology Solutions
51
Gajakarnan KandiahCognizant Technology Solutions
50
Srinivasan VeeraraghavacharyCognizant Technology Solutions
63
James LennoxCognizant Technology Solutions
53
Venkat KrishnaswamyCognizant Technology Solutions
64
Ramakrishna ChintamaneniCognizant Technology Solutions
48
Sean MiddletonCognizant Technology Solutions
36
Dharmendra SinhaCognizant Technology Solutions
55
Malcolm FrankCognizant Technology Solutions
51
It operates through four segments Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. MERCK DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 69000 people. Merck Co (MRCK34) is traded on Sao Paulo Exchange in Brazil and employs 44 people.

Management Performance

Merck Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Cristal Downing, Ex Officer
Jennifer Zachary, General Counsel
Rochelle Lazarus, Independent Director
Wendell Weeks, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Paul Rothman, Director
Mary Coe, Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Caroline Litchfield, Ex CFO
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Jennifer Mauer, VP Communications
Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health
Leslie Brun, Independent Director
Inge Thulin, Director
Pamela Craig, Director
Patricia Russo, Independent Director
David Williams, Ex Officer
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Lisa LeCointeCephas, VP Officer
Robert Davis, CFO and Executive VP
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Chief Marketing Officer
Peter Dannenbaum, VP Relations
Clark Golestani, CIO and Executive VP
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Chief Human Resource Officer
Jim Scholefield, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman, CEO and Pres
Frank Clyburn, Chief Commercial Officer
Robert JD, CEO Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Merck information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.